Efficacy of retreatment with IMiD-based therapy (lenalidomide, pomalidomide and thalidomide) in patients refractory both to IMiDs and anti-CD38 antibodies
Latest Information Update: 08 Jan 2021
At a glance
- Drugs Lenalidomide (Primary) ; Pomalidomide (Primary) ; Thalidomide (Primary)
- Indications Myeloma
- Focus Therapeutic Use
- 08 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology